Takeda and Alnylam - Billion-dollar deals

Who: Takeda
With: Alnylam
What: $1 billion licensing deal

Scoop: In May, Takeda continued its expansion in the U.S. with a $1 billion move into the RNAi field. In an alliance with RNAi powerhouse Alnylam, Takeda gained RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional therapeutic areas in the future. Alnylam landed $100 million in up-front cash and an additional $50 million in near-term technology transfer payments. Takeda can expand the partnership in the future to include additional fields, with a payment of $50 million to Alnylam for each additional field. Finally, Alnylam will receive $171 million in milestones, along with royalties, for each product developed as part of the deal.

Takeda and Alnylam - Billion-dollar deals
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.